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CLINICAL PROBLEM: PREDICTING METASTATIC PROPENSITY
Our ability to detect and successfully treat localized cancers has improved appreciably in recent years. However, metastatic disease presents a continuing therapeutic challenge and is the most common cause of cancer-related death. Thus, there is an emphasis on the diagnosis of cancers at an early stage, when they are localized and most likely to be curable. Although screening for early-stage disease is logical, its utility is limited by the inability of conventional diagnostic and histologic parameters to predict accurately the true extent and prognosis of a substantial proportion of clinically localized cancers (1) (2) (3) . This limitation is due, in part, to the inherent limitations and subjectivity of current grading and staging systems (4, 5) .
The incidence of disease recurrence in surgical patients treated for prostatic and breast cancers illustrates this problem particularly well. Although we have a wealth of clinical and biologic information on these diseases, a large percentage of apparently resectable and theoretically curable lesions is found to be more advanced at the time of resection than envisaged, resulting in a substantial failure rate after attempted curative surgery (6) (7) (8) . In studies of prostate cancer patients (9) (10) (11) , even when patient selection excludes men with factors predicting poor prognosis (e.g., poorly differentiated histology, high prostate-specific antigen [PSA] levels, and clinical suspicion of local invasion), the relapse rate after radical retroperitoneal prostatectomy has approached 20%-30%. Similarly, one third of surgical patients with lymph node-negative breast cancer will develop metastases, while the other two thirds, despite receiving no chemotherapy, will not (12) . Even in patients with small tumors and tumor-negative lymph nodes (T1N0), there is a 15%-25% likelihood of distant metastases (8) .
Since the current staging systems for breast and prostate cancers do not accurately identify those patients curable by regional treatment alone, the evaluation of additional parameters associated with the metastatic phenotype will be very important for the differentiation of patients curable by surgery alone from those requiring systemic therapy. For instance, men at high risk for relapse of prostate cancer can be identified [e.g., serum PSA level >10 ng/mL; clinical stage T1 or T2 with >50% of tissue at Gleason grade 4 (3,4) on biopsy or clinical stage T3 prostate cancer] and would be immediate candidates for adjuvant antimetastatic therapies if they existed (10, 11, (13) (14) (15) (16) . Likewise, breast cancer patients with particularly poor prognoses can be identified by the detection of high microvessel counts concurrent with low expression of Nm23 and/or E-cadherin in the primary tumor (12) (13) (14) (15) (16) (17) . In fact, these parameters are better prognostic biomarkers than the conventional analysis of tumor size and grade. The information obtained from the simultaneous evaluation of biomarkers such as these have the potential to lead to a reduction in the morbidity among those patients not requiring chemotherapy and possibly identify those patients requiring more aggressive therapies than indicated by current methods.
Overall, it is clear that there is a critical need for markers that will distinguish accurately those histologic lesions and disseminated cells that have a high probability of causing clinically important metastatic disease from those that will remain indolent (5, 15) . Concerns have been raised that "metastasis" has often occurred by the time of diagnosis of the primary tumor, the implication being that it is then too late for antimetastatic therapy to be of use (18) . However, the mere spread of cancer cells into the vasculature or to a secondary site does not constitute metastasis. Development of clinically significant metastases requires that a cancer cell complete a series of well-defined steps, generally referred to as the metastatic cascade (13) . If a cell fails to complete any one of these steps, overt metastases will not develop (13) (14) (15) .
The clinical importance of disseminated cancer cells (detected by sensitive methods such as reverse transcriptionpolymerase chain reaction [RT-PCR]) has become an issue of considerable interest (19) . Several such studies (16, 20) have reported the detection of tumor-derived cells in the circulation and bone marrow without future development of disease. Other reports have demonstrated an increased risk of disease recurrence in patients with bone marrow micrometastases both for prostate cancer [by the detection of messenger RNA transcripts for PSA (21) ] and breast cancer [by the detection of cytokeratinpositive cells (22) ]. Even in these later studies, however, the majority of patients with tumor cell-positive bone marrow samples did not actually develop recurrent disease, although the proportion with recurrence could increase given extended time for patient follow-up. The discrepancy regarding the clinical importance of disseminated cells is likely due to differences in the experimental approaches used to identify cells (i.e., RT-PCR versus immunohistochemical detection).
Tumor cell growth at the site of metastasis is an important clinical target, since cells must survive and proliferate to grow into overt, macroscopic metastases. The first step toward developing effective therapies to inhibit such growth is to identify the genes/proteins that regulate metastatic colonization. To this end, a growing number of laboratories are focusing translational research efforts on the discovery of genes that specifically regulate the metastatic ability of cancer cells. For example, several metastasis-promoting genes-including WDNM-1, WDNM-2, MMP11 (stromelysin-3), MTA1, and ERBB2-have been identified in association with the development of metastatic breast cancer (23) (24) (25) (26) (27) . One must keep in mind, however, that it takes the coordinated expression of many genes to allow the development of metastases (28, 29) . Thus, while it is relatively easy to demonstrate an association for a given gene with metastatic ability, it is difficult to prove that a particular gene is essential.
On the other hand, it only takes one gene to block metastasis, since inability to complete any step of the metastatic cascade renders a cell nonmetastatic. Metastasis-suppressor genes suppress the formation of spontaneous, macroscopic metastases without affecting the growth rate of the primary tumor. It has now been more than 10 years since the discovery of the first metastasis-suppressor gene nm23 (NME1) (30) . Since then, both in vitro and in vivo (e.g., animal) studies (15, (30) (31) (32) have documented the important role of the loss of metastasis-suppressor gene function in the acquisition of metastatic ability.
While the initial motivation for these studies was the development of new diagnostic markers of metastasis, the biologic approach used to identify metastasis-suppressor genes has provided surprising insights into the in vivo mechanisms regulating the formation of metastases. We anticipate that identifying the molecular pathways that regulate metastatic colonization and growth control at the secondary site will provide additional, potentially novel therapeutic targets for the treatment of metastatic disease. The purpose of this review is 1) to present the evolving view of the mechanisms that regulate metastasis, 2) to describe the functional strategy used to identify metastasissuppressor genes and discuss important principles learned from these studies, 3) to document the known metastasis-suppressor genes and report new evidence that supports their role in the regulation of growth control at the secondary site, and 4) to discuss the multidisciplinary approach needed to translate metastasis-suppressor genes into clinical tools.
REGULATION OF METASTATIC PROPENSITY-EVOLVING PARADIGMS
Metastasis is defined as the formation of progressively growing secondary tumor foci at sites discontinuous from the primary lesion (15) . This process is illustrated by the spontaneous hematogenous metastasis of tumor cells to the lung (Fig. 1, A) . The formation of a primary tumor requires a cadre of molecular and cellular alterations that enable a cell(s) to circumvent normal growth control mechanisms as well as to manipulate its local environment (14) . These changes include the development of a blood supply once the focus of transformed cells grows beyond a size that can be nourished by nutrient or metabolite diffusion (33, 34) . Tumor progression and the acquisition of metastatic competence require additional changes in gene expression (e.g., protein-degrading enzymes and adhesion molecules) that culminate in a malignant phenotype. After invasion into adjacent tissues, tumor cells disseminate via blood vasculature or lymphatics and travel individually or as emboli made up of tumor cells or tumor and host cells. At the secondary site, cells or emboli arrest either because of their physical size or by binding to specific molecules in particular organs or tissues (15, 35) . For disseminated cells to grow into overt metastases, they must survive and proliferate in the vasculature or in the surrounding tissue after extravasation. The formation of clinically important metastases depends on the completion of every step of this cascade, the last of which is metastatic colonization (Fig. 1) (14) .
The presence of isolated cells at a secondary site represents a risk to the patient. Cells getting to the secondary site certainly have the potential to colonize; therefore, it is crucial not to ignore the presence of neoplastic cells anywhere. On the other hand, as we will show, the mere presence of cells does not necessarily mean that metastatic colonization will occur. The challenge is to determine how to discriminate between disseminated cells that will form overt metastases from those that will not.
Cancer metastasis, both clinically and experimentally, is known to be inefficient (36) . In experimental models, fewer than 0.1% of cells injected into the circulation go on to form secondary tumors (15, 37) . While many factors contribute to the observed inefficiency of metastasis formation, those considered to be most important include the low survival rates of cells in the circulation and the low percentage of cells that successfully escape from the vasculature into surrounding tissues (18) . At this time, there is some question as to whether postextravasational growth control or growth within a vessel are more predominant (38) . This process has, for the most part, been studied using assays in which the number and kind of cells injected are known and the numbers and sizes of metastases formed are assessed (18, 39) . The processes that are responsible for metastatic efficiency in vivo remain hidden; thus, mechanistic paradigms have largely been based on logical inference rather than on direct observation. The development of new technologies has enabled researchers to test the possibility that cancer cell dissemination, arrest (nonspecific arrest and/or specific adhesion events), and growth at the secondary site are critical determinants in metastasis formation.
The ability to observe single cells in vivo has been greatly enhanced by improvements in intravital microscopy and the use of vital fluorescent dyes like green fluorescent protein (GFP) (18, 40) . Studies that couple these two powerful techniques have added greatly to our knowledge of the metastatic processes following tumor cell entry into circulatory compartments. The use of in vivo video microscopy allows for the direct observation of experimental metastasis over time (39) . Cancer cells can be fluorescently labeled in vitro and then injected into an animal. The cells can then be viewed at different time points, by both fluorescence and oblique transillumination, in thin tissues or superficial (ഛ50 m) regions of thick tissues in vivo (39) . Experiments using this technology have demonstrated that, in contrast to the long-held belief, the vast majority of cancer cells in the microcirculation manage not only to survive there but also to extravasate into the surrounding tissue within 1-2 days (41, 42) . Such studies have translated well into the clinical arena. Specifically, the vast majority of clinical studies using RT-PCR to detect prostate tumor cells in the peripheral circulation and bone marrow found no association between the detection of disseminated cells and treatment failure (16, 20) . Of interest, in a recent study of breast cancer patients (22) , detection of cytokeratinpositive cancer cells in the bone marrow was associated with the development of overt metastases and death. The apparent difference between these two findings may be due to differences in study design (e.g., detection methods and markers used) or in factors that influence the growth of disseminated cancer cells at the metastatic site. Additional studies will be necessary to distinguish between these possibilities. Taken together, the clinical and experimental evidence supports the observation that dissemination from the primary tumor site is a frequent event. Furthermore, these independent and complementary studies strongly suggest that growth control of individual disseminated cells determines the efficiency of metastatic colonization.
Metastatic colonization is the lodging and subsequent growth of disseminated cancer cells to form clinically significant metastases ( Fig. 1, B ). To proliferate, surviving disseminated tumor cell(s) must be able to initiate cell-appropriate, contextdependent signaling cascades, which enable them to survive, enter the cell cycle, and divide. While disseminated cells are likely to be present in numerous organs, only certain environment(s) appear to allow their survival and subsequent growth (37, 43, 44) . Intercellular interactions with the stroma and with other tumor cells are critical for tumor cell survival and involve the activation of adhesion-dependent survival pathways, such as those described for E-cadherin (45, 46) and integrin molecules (47) . Clusters of proliferating cells grow into lesions consisting of a few hundred that can be detected reliably by histologic methods. Cells within such microscopic lesions can receive oxygen and nutrients by diffusion. Progressive growth of microscopic lesions into overt or macroscopic metastases (>1 mm in diameter) requires that the fraction of proliferating cells exceed the fraction that are quiescent or apoptotic. This transition from microscopic to macroscopic metastasis has often been referred to as the switch to an angiogenic phenotype or the angiogenic switch (48) . This terminology implies that microscopic metastases exist in one of two states: Either the lesion is angiogenic (forming new blood vessels), or it is not. However, the progression from a "microscopic lesion" to an overt metastasis is more accurately described in terms of growth control. Indeed, the interchangeable use of "angiogenesis" and "growth" has been a source of confusion. This progression may occur over a period of months or even years and is not necessarily dependent on new blood vessel formation. Vascularization is, in fact, a late step in metastatic colonization (49) . Recent studies have shown that, in addition to the induction of classical neovascularization via endothelial cell recruitment, tumor cell masses can develop a blood supply by alternative means, such as the cooption of pre-existing host vessels (49) or by the formation of tumor channels, a process referred to as vascular mimicry (50) . As we will describe in the following paragraphs, recent data from our laboratories suggest that a subset of metastasis-suppressor genes inhibits early steps in metastatic colonization, prior to the need for development or recruitment of vessels.
IDENTIFICATION OF METASTASIS-SUPPRESSOR ACTIVITY: A FUNCTIONAL APPROACH
Metastasis-suppressor genes suppress the formation of (spontaneous) macroscopic metastases. As their name implies, these genes are distinct from oncogenes, which promote cellular transformation, and tumor-suppressor genes, which suppress tumor growth. While the first metastasis-suppressor gene, nm23, was identified by a complementary DNA (cDNA) subtraction approach, the majority of metastasis-suppressor activities identified to date have been discovered using microcell-mediated chromosomal transfer (MMCT) ( Table 1 ). The choice of the MMCT strategy was logical, since the existence of metastasissuppressor genes was originally implicated by the results of somatic cell fusion studies, the precursor of MMCT (51) (52) (53) (54) . The techniques for the generation of genetically stable somatic cell hybrids were developed in the early studies by Barski et al.
[reviewed in (55) ]. In most instances, fusion between malignant and normal cells results in hybrid cells that are suppressed in their tumorigenic capacity (56) . Ichikawa et al. (57) were the first researchers to identify specific chromosomal losses associated with the reacquisition of metastatic ability. In their study, fusion of nonmetastatic with highly metastatic Dunning rat prostatic cancer cells resulted in nonmetastatic hybrids. More important, the tumorigenicity (e.g., tumor formation and latency period) and in vivo growth rates of the primary tumors of hybrid clones containing a full complement of rat chromosomes were not affected. At the experimental end point, none of the animals bearing hybrid tumors developed distant metastases. However, when the nonmetastatic primary tumors were serially passaged in vivo, animals occasionally developed distant metastases. Cytogenetic analysis of these metastatic revertants revealed a consistent loss of a copy of rat chromosome 2. This critical study suggested that the loss of specific chromosomes could increase the metastatic potential of prostate cancer cells without affecting growth rate or tumorigenicity.
The observation of a metastasis-suppression activity being associated with a specific chromosome coincided with the development of MMCT as a technique for the study of genes encoded by individual human chromosomes (51) (52) (53) (54) (58) (59) (60) (61) . In this approach, summarized in Fig. 2 , well-characterized donor cells, carrying a single human chromosome tagged with a selectable marker or markers (e.g., neomycin phosphotransferase, etc.), are used to transfer the chromosome of interest into recipient cells (62) . Briefly, donor cells are sequentially treated with Colcemid, to depolymerize microtubules, and cytochalasin-B, to depolymerize actin bundles. The treated cells are centrifuged, and the resulting pellet contains the microcells (63) . Microcells are, in effect, micelles that contain a single chromosome or multiple chromosomes. To enrich for those containing a single chromosomes, the microcells are size fractionated by sequential filtration through polycarbonate membranes of decreasing pore size. Microcells become attached to recipient cells in the presence of phytohemagglutinin and then become fused with the addition of polyethylene glycol. Recipient cells containing human chromosomes are selected in G418-containing media and then characterized by molecular and cytogenetic methods, such as sequence tagged-site PCR, karyotyping, and fluorescence in situ hybridization (63, 64) . The complete characterization of the hybrids under study is critical, since it provides information on the addition and/or deletion of donor and recipient chromosomal material, as well as any rearrangements that may have occurred during MMCT. Several laboratories have employed the technique of MMCT to test the functional significance of chromosomal alterations, such as loss of heterozygosity (LOH), observed in clinical samples. In addition, the use of MMCT, in combination with positional or expression-based cloning techniques, has allowed the functional identification of genes conveying phenotypes, such as senescence or tumor and metastasis suppression (15, 65, 66) . A review of the literature shows that transfer of a given chromosome can have different phenotypic effects that are dependent on the characteristics of the recipient cell line. For example, the transfer of human chromosome 7 by MMCT into immortalized SUSM-1 fibroblast cells induces senescence (67) , whereas transfer of the same chromosome into choriocarcinoma cells results in suppression of tumor growth in vivo (68) . Such results have enabled the definition of complementation groups for particular chromosome functions. The potential outcomes of transferring a particular chromosome into highly metastatic cells are summarized in Fig. 2 .
Studies using highly metastatic Dunning rat prostatic cells as the recipients for chromosomal transfer (63, 64) showed that chromosomes 12 and 17 specifically suppressed the metastatic ability of these cells. The observed metastasis suppression had no effect on tumor growth rate. Of interest, in analogous studies of human prostate cancer cell lines, transfer of these chromosomes suppressed the cells' tumorigenicity (69, 70) . These findings could result from at least three alternative mechanisms. First, a given chromosomal region may encode a number of different genes, one or more of which may be active as a tumorsuppressor gene in human prostate cancer cells but be inactive or not expressed in rat prostate cancer cells. Second, genes may function as metastasis-suppressor genes when expressed in rat prostate cancer cells but may be inactive or not expressed in human prostate cancer cell lines. Third, gene(s) that lie in the same chromosomal region may have different functions, depending on the context (i.e., cell type) in which they are expressed.
In the third scenario, the effect of the gene product may be limited or determined by the recipient cells. We refer to this scenario as the "cellular hard-wiring" hypothesis. 1 For example, human prostate cancer cell lines compared with Dunning rat prostate cancer cell lines are weakly metastatic in spontaneous metastasis assays (62) . These differences in their in vivo biologic activities could be the result of genetic differences between the tumor cells, or they could result from an epigenetic mechanism, such as differential tumor-stromal interactions. The nature of cellular interactions with the extracellular matrix can regulate tissue-specific gene expression, since cells form an elaborate three-dimensional network composed of the nuclear, cytoskeletal, and extracellular matrices (27, 71) . Thus, the differential effects of a given chromosome transferred into different cell types can be the result of differential expression of the genes on the chromosome as determined by the way a cell responds to its environment.
During the past decade, several human chromosomes have been functionally tested through the use of MMCT, and metastasis-suppressor activities have been reported on chromosomes 1, 6, 7, 8, 10, 11, 12, 16, and 17 (63,64,72-82) (Table 1) . Such functional studies, combined with positional and expressionbased gene cloning techniques, have enabled the identification of KAI1, KISS-1, MKK4/SEK1, and BRMS1 as metastasissuppressor genes. 
A9 donor cells containing a single human chromosome are used for the preparation of microcells that will be transferred to the recipient cell lines. Stable microcell hybrids are selected and characterized by molecular and cellular methods. To screen the microcell hybrids for the minimal metastasis-suppressor region, one employs the following techniques: FISH, karyotyping, and PCR amplification for human specific sequences using STS markers. Ultimately, the presence or absence of a suppressor region is determined by subcutaneous injection of the hybrids into the flanks of immunodeficient mice (63) . Inclusion of a variety of controls is critical for the definition of metastasis-suppressor activity in vivo. The potential outcomes of in vivo studies using control, suppressed, and unsuppressed hybrids are illustrated at left. FISH ‫ס‬ fluorescence in situ hybridization, PCR ‫ס‬ polymerase chain reaction, STS ‫ס‬ sequence-tagged site, and PEG ‫ס‬ polyethylene glycol.
Metastasis-Suppressor Genes
As discussed earlier, metastasis-suppressor genes suppress the formation of spontaneous, macroscopic metastases without affecting the growth rate of the primary tumor. To date, five genes, nm23 (NME1), KAI1, KiSS1, BrMS1, and MKK4 (MAP2K4), have been shown to meet the criteria of a metastasis-suppressor gene [see Table 2 ; (31, 32, ]. The role of other genes, such as CD44 and maspin/PI5, in metastasis suppression is less well defined (102, (120) (121) (122) (123) (124) (125) (126) (127) (128) (129) (130) (131) . The potential mechanism of action of all of these genes has been inferred by analogy to other family members and observations in model systems. How these genes and their protein products function to suppress metastasis in vivo is the subject of enthusiastic study. Decreased expression of the suppressor gene is the key parameter determining metastatic potential and may occur by a variety of mechanisms, not necessarily LOH (32, 91) . To date, nm23 (NME1) and KAI1 are the best-characterized metastasissuppressor genes.
nm23 (NME1)
The prototypical metastasis-suppressor gene, nm23, was identified in the murine K1735 melanoma by use of subtractive hybridization (a method to identify genes differentially expressed between two cell lines), and six human homologues have been identified (90) . Loss of Nm23-H1 expression is associated with metastatic potential in many, but not all, late-stage tumors (91) . Transfection of nm23-H1 cDNA into highly metastatic murine melanoma, rat mammary adenocarcinoma, and human breast cancer and melanoma cells reduces their invasiveness and metastatic ability in vivo (91) . In cancers, such as lung, colon, prostate, etc. [reviewed in (87) ], where no alterations in the expression pattern of Nm23-H1 are evident, it is possible that the biologic function of Nm23-H1 does not influence malignant progression in these cell types. Alternatively, its effects may be inhibited by alternate mechanisms. The mechanism of action for metastasis suppression by Nm23 still remains unknown; however, evidence suggests that it is phosphorylated and may be involved in a novel signaling pathway that, in turn, controls cell motility (84, 87) .
KAI1
The localization of metastasis-suppressor activity to rat chromosome 2 in the cell fusion experiments by Ichikawa et al. (57) prompted the search for homologous metastasis-suppressor genes for human prostate cancer. The first of such genes identified was KAI1. MMCT was used to transfer human chromosome 11 into Dunning AT6.1 and AT3.1 rat prostate cancer cells, and the resulting microcell hybrids were assayed for metastasis suppression in immunodeficient mice (81) . These studies led to the identification of the metastasis-suppressor gene KAI1, which maps to 11p11.2-p13 (101). The metastasis-suppressor activity of KAI1 was subsequently demonstrated by transfecting it into AT6.1 cells and assaying the metastatic ability of individual transfected control cell lines in severe combined immunodeficient (SCID) mice (101) . Reports (101, 110) suggest that expression of KAI1 decreases both the invasiveness and motility of cells in vitro. Additional studies show that KAI1 transfectants exhibit enhanced Ca 2+ -independent aggregation, indicating that KAI1 expression alters cell-cell interactions (109) . The metastasis-suppressor activity of KAI1 was subsequently demonstrated by its transfection into AT6.1 cells and assaying the metastatic ability of individual transfected control cell lines in SCID mice (101) . Lowered expression of KAI1 has also been associated with progression in a wide variety of cancers, including pancreatic, hepatocellular, bladder, breast, and non-smallcell lung cancers (31, (133) (134) (135) (136) , as well as esophageal cell carcinomas (137) and squamous and lymphoid neoplasms (138) . These data suggest that KAI1 has a conserved metastasissuppressor function. Furthermore, these studies demonstrate that metastasis-suppressor genes can be developed as clinical markers even before their biochemical mechanism of action has been elucidated.
EMERGING ROLE OF METASTASIS-SUPPRESSOR GENES IN THE REGULATION OF METASTATIC GROWTH
While it is tempting to speculate on the mechanism of action of genes shown in Table 2 , examination of how genes, such as MKK4 or BRMS1, suppress metastasis will require construction of appropriate biochemical constructs and identification of in vitro conditions that will enable us to conduct meaningful biochemical and molecular studies. As a first step to accomplishing this goal, our laboratories have initiated studies designed to examine the step in the metastatic cascade inhibited by a chromosome or gene of interest. As an example of these studies, we will present recent work on the metastasis-suppressor activity encoded by chromosomes 17 and 6. These studies have brought us closer to defining mechanisms of metastasis suppression.
Chromosome 17
We have reported the identification of discontinuous portions of human chromosome 17 (D17S952 → D17S805, D17S930 → D17S797, and D17S944 → qter) that together suppress the metastatic ability of AT6.1 Dunning rat prostatic cancer cells when introduced via MMCT (63, 80) . PCR and Southern blot analyses demonstrated that three of the four markers on 17p13, including HIC1 and TP53, and 12 of the 13 markers in 17q21-23, including BRCA1 and the metastasis-suppressor gene NME1 (nm23), were not retained in this region (63) . AT6.1 microcell hybrids containing this portion of chromosome 17 were tested in vivo in spontaneous metastasis assays. Spontaneous metastasis is measured by the ability of tumor cells to form a locally growing tumor at the site of injection and disseminate and grow at to secondary sites thereafter.
At the experimental end point, the number of overt surface metastases observed in the lungs from mice with AT6.1-17 tumors was reduced 15-to 30-fold compared with lungs from mice bearing parental AT6.1 tumors (63) . This suppression could be due to the inhibition of any step within the metastatic cascade. We reasoned that examination of the biology of metastasis suppression would provide clues to the identity of genes responsible for suppression of metastatic growth. A series of in vivo experiments were conducted, and no evidence was found to suggest that there is a decrease in the number and/or viability of tumor cells colonizing the lung (80) .
On the basis of these findings, we hypothesized that a gene or genes encoded by the suppressor region of chromosome 17 function by inhibiting the growth of metastases in the lung (139) . To test this possibility, AT6.1-17 cells were transduced with a ␤-galactosidase reporter gene construct (AT6.1-17T␤gal cells) (Table continues) and tested in spontaneous metastasis assays (2) . At the experimental end point, animals were killed and the excised lungs were stained for ␤-galactosidase expression. This approach allowed the visualization of microscopic AT6.1-17␤gal surface metastases. Subcutaneous injection of AT6.1 parental cells resulted in the formation of a mean number of 97 overt surface metastases (detected using Bouin's fixation) per lung ( Fig. 3, A; left) . As expected, the number of overt macroscopic metastases after the subcutaneous injection of AT6.1-17-T␤gal cells was greatly reduced ( Fig. 3, A; middle) . In contrast, when lungs removed from the mice carrying AT6.1-17-T␤gal tumors were stained for ␤-galactosidase activity, numerous blue-staining microscopic ND *TGF␤ ‫ס‬ transforming growth factor-beta, ND ‫ס‬ not determined, MMCT ‫ס‬ microcell-mediated chromosomal transfer, cDNA ‫ס‬ complementary DNA, NE ‫ס‬ not examined, exp. mets. ‫ס‬ experimental metastases, spont. mets. ‫ס‬ spontaneous metastases, PCR ‫ס‬ polymerase chain reaction, AS ‫ס‬ antisense, EST ‫ס‬ expressed sequence tag.
†Cell motility was determined in chemotaxis assays by use of Boyden chambers, in phagokinetic track assays on coverslips, or by cinematography studies. Invasion was measured by migration through Matrigel or reconstituted basement membranes in Boyden chambers. Colony formation was evaluated in soft agar. Cell proliferation was measured by counting viable cells using a hemocytometer. Cell adhesion was evaluated by the ability of cells to form conjugates with lymphokine-activated killer cells (LAK), the ability to adhere to tissue culture plates coated with laminin, fibronectin, collagen type I, or collagen type IV in the absence of fetal bovine serum (FBS), or by the ability to remain adherent to tissue culture plates after the removal of FBS and the addition of oligonucleotides and TGF␤. Immunosensitivity was determined in chromium-release assays with LAK cells. Cell aggregation was examined by culturing single-cell suspensions in Puck's saline plus 0.8% FBS. Cell spreading over extracellular matrix substrates was monitored over time by photography.
‡Additional clinical studies have examined the expression of Nm23 in hepatocellular, gastric, ovarian, and cervical carcinomas (87) . §HD3 and U9 are sublines of the human colon carcinoma line, HT29, and differ in their responses to TGF␤. Inverse correlations between KAI1 protein and/or messenger RNA expression and malignant potential have been observed in pancreatic, non-small-cell lung, bladder, hepatocellular, and esophageal squamous cell carcinomas.
¶Does not fit the classic definition of a metastasis-suppressor gene.
metastases were observed ( Fig. 3, A; right) . Of interest, the mean number of AT6.1-17-T␤gal micrometastases (i.e., 62 ± 12 standard error [SE]) detected by this method is on the same order of magnitude as the mean number of macroscopic AT6.1 metastases (i.e., 97 ± 6 SE). These results demonstrate that AT6.1-17 cells do escape from the primary tumor and arrive in the lungs but do not form large metastatic foci (139) . Development of overt metastases was associated with loss of the metastasissuppressor region of chromosome 17 (139) . Because of the similarity between our findings to the angiostatin-mediated dormancy reported by Holmgren et al. (140) , we investigated the possibility that AT6.1-17 primary tumors secrete a substance that suppresses the growth of its own metastases (139) . For this experiment, 2 × 10 5 AT6.1-17 cells were injected subcutaneously into the flanks of SCID mice, which were then divided into two experimental groups. Once the tumors reached a volume of 1 cm 3 , they were surgically removed from the mice in the first group, while those in the second group were left intact, although a contralateral sham surgery was performed. It was anticipated that if the AT6.1-17 primary tumor secreted a substance like angiostatin, which suppresses the growth of its own metastases, then a substantial increase in the number of overt metastases should develop in the lungs of mice in which the primary tumors had been removed. However, after approximately 65 days after injection, the animals were killed and examination of the lungs from both groups showed no difference in the numbers of overt macrometastases (139) . Thus, these studies found no evidence for an antiangiogenic mechanism in this model.
Taken together, our data suggested that AT6.1-17 cells escape from the primary tumor but are growth inhibited at the secondary site (139) . If this is an early event, we predicted that viable, disseminated AT6.1 and AT6.1-17 cells should be present in the lung at very early time points. We found that viable cells could be harvested from the lungs of both AT6.1 and AT6.1-17 tumor bearers as early as 18 days after injection (Fig.  3, B) . Our preliminary time-course data show that AT6.1-17 cells disseminate and lodge in the lungs but have an extended latent period as compared with AT6.1 parental cells.
Chromosome 6
On the basis of the high incidence of chromosome 6 abnormalities in late-stage human melanoma (141), we introduced an intact chromosome 6 into the highly metastatic C8161 human melanoma cells by MMCT. Parental cells formed tumors in every mouse given an intradermal injection of 1 × 10 6 cells, and more than 90% of the mice developed regional lymph node and lung metastases. In contrast, chromosome 6-C8161 hybrids (neo6/C8161) were still tumorigenic but completely suppressed for metastasis (142) . Intravenous injection of neo6/C8161 cells also did not produce metastases. In a recent study (143) , introduction of a version of a chromosome 6 with deletions on the long arm allowed refinement of the metastasis-suppressor locus to a 40-megabase (Mb) region represented by chromosomal bands 6q16.3-q23.
The mechanism of action for the metastasis-suppressor protein from the gene on chromosome 6 was studied using a variety of in vitro and in vivo techniques. The neo6/C8161 cells were still locally invasive, and cells were even detected in efferent vessels. This finding implied that the step(s) in the metastatic cascade inhibited by introduction of chromosome 6 occurred subsequent to intravasation. The identity of those steps was not further elucidated using in vitro assays mimicking adhesion, invasion, motility, or growth. No important differences between the metastatic and nonmetastatic cells were observed using the many in vitro assays (72, 73, 141, 142) .
For a better definition of the step(s) in metastasis blocked by addition of chromosome 6, cells that constitutively express GFP were engineered. GFP-tagged C8161 and neo6/C8161 cells were injected intravenously into athymic mice. C8161, as expected, formed overt metastases, but neo6/C8161 cells did not. Microscopic metastases (single cells or clusters of <10 cells) were observed in the lungs following neo6/C8161 cell injection, suggesting that these cells lodged in the lungs but failed to proliferate (144) . For the determination of whether the fluorescing cells were viable, they were isolated from the lung up to 60 days after injection and grown in culture. On injection into the skin of athymic mice, the neo6/C8161 cells isolated from the lung grew at rates similar to those of previously injected neo6/C8161 cells. This result implies that the gene or genes on chromosome 6 interfere specifically with growth-regulatory responses in the lung but not in the skin.
FROM GENE DISCOVERY TO CLINICAL UTILITY
This review has focused on the identification and development of metastasis-suppressor genes as new additions to our molecular armamentarium. As translational researchers, our immediate goals are 1) to improve the ability of the pathologist to distinguish unambiguously malignant from indolent lesions and 2) to help the clinician differentiate tumors that are highly likely to metastasize from those that are not. The practical question, therefore, is: How can we use these genes, or the pathways that they regulate, to improve patient management? When the search for metastasis-suppressor genes was initiated in the late 1980s, the major challenge was the identification of candidate genes. Recently, however, there has been an explosion in the genetic information that is instantly available. Furthermore, because of the efforts of independent laboratories and cooperative efforts, such as the Cancer Genome Anatomy Project of the National Cancer Institute (Bethesda, MD), cancer transcriptomes and proteomes will soon be available (145, 146) . New technologies will continue to increase our ability to dissect molecular pathways in individual cells within human cancers. While this wealth of information will no doubt be of use, work from the groups of Bissell, Cunha, and Chung (147) (148) (149) (150) (151) (152) (153) (154) has clearly demonstrated that tissue structure determines, or at least greatly influences, gene expression and function. Thus, it may be extremely difficult to predict the importance of genes expressed in individual microdissected cancer cells to the biology of the intact tumor, the behavior of which is determined by complex interactions among a population of cells. The present challenge is to identify the genes that are functionally important in the acquisition of metastatic ability. Achieving this goal will require the use of well-characterized, in vivo (animal) models coupled with clinical correlative studies. It must be emphasized that in vitro models do not accurately reflect in vivo metastasis (155) . Indeed, none of the metastasis-suppressor genes described herein could have been identified using traditional in vitro assays. Given the inherent variability and nonlinear behaviors of biologic systems, it is probable that no one model will prove to be adequate to separate out the contributions of the multiplicity of genes involved in the development of metastases. Thus, it is more advantageous to focus studies on a particular model and tease out important cellular pathways modulated by a particular gene of interest in that model and then to test and verify the importance of the target pathway in clinical disease as well as in additional model systems.
Technologic advances are enabling us to examine the metastatic process and the genes that regulate it in new ways. This ability has led us to re-evaluate fundamental concepts concerning the determinants of metastatic propensity. In the past, the escape of cells from the primary site was viewed as the ratelimiting step for the development of metastases. The clinical implication was that disseminated cancer cells were destined to grow into lethal metastases; thus, they were not a target for therapeutic intervention (18) . Findings from clinical studies and basic research from several independent laboratories have shown that survival and subsequent growth of extravasated cancer cells at the secondary site may determine metastatic efficacy. These observations are driving our laboratories and others to reconsider the role of endothelial cell-tumor cell interactions in survival, signaling, and growth control cascades to develop new strategies for controlling the growth of disseminated cancer cells (39, 45, 156) .
As metastasis researchers, we find ourselves in the midst of a revolution. In preparing this review, we considered the parallels between recent developments in our field and the development of the field of molecular biology. Much of early molecular biology was pursued by individuals who were not trained as biologists, but as physicists, such as Max Delbrück (157) . We are respectful of the observations of Erwin Schrödinger, the father of statistical mechanics, who observed that, "all of the physical and chemical laws that are known to play an important part in the life of organisms are of the statistical kind. The behavior of such systems depends entirely on a large number of molecules that cooperate to form the observed function or phenotype" (158) . Although this comment was made in regard to normal biologic processes, it is equally applicable to the multiple genetic changes that are required for the acquisition of metastatic ability. Metastasis is a complex, multigenic phenotype. As such, multiple markers will be needed for the accurate assessment of the metastatic ability of tumors and tumor cells. This need is highlighted by the tremendous impact of seemingly trivial experimental manipulations on the outcome of metastasis assays (155) . Parallels have been drawn between the behavior of cancer cells and complex adaptive systems (159, 160) . As such, very small changes in initial conditions may produce an outcome of such great diversity as to appear random (159) . Ultimately, we believe that, to translate our molecular findings into meaningful markers, we will have to go beyond our traditional areas of expertise and work with mathematicians, computational biologists, and others to take this revolution from bench to bedside.
